
EULAR 2024 Review Podcast
The IMID Forum
Analysis of Sustained Remission Study and Safety of JAK Inhibitors
The chapter covers a remission study in patients with active disease, showing a high flare rate after treatment cessation, and explores predictors of inactive disease. It also evaluates the safety profile of JAK inhibitors versus TNF and IL-17 inhibitors, revealing no elevated risks in cardiovascular disease, VTEs, or cancer at multiple time points.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.